Galeterone is primarily used in the treatment of prostate cancer, particularly in patients with castration-resistant prostate cancer (CRPC). It functions by targeting multiple pathways involved in cancer progression. The compound acts as an androgen receptor antagonist, inhibits androgen synthesis, and promotes degradation of the androgen receptor, which collectively help suppress tumor growth driven by androgen signaling. Due to this multi-modal mechanism, galeterone has been investigated in clinical trials to evaluate its effectiveness in improving outcomes for men with advanced prostate cancer, especially in cases where other treatments have failed. Its development represents a strategic approach to overcoming resistance mechanisms in hormone-dependent cancers.